ORCID Profile
0000-0002-2498-5946
Current Organisation
Peter MacCallum Cancer Centre
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 05-2021
Publisher: Royal Society of Chemistry (RSC)
Date: 2021
DOI: 10.1039/D1SC01422F
Abstract: Enzymatic bioconjugation to introduce positron-emitting radionuclides ( 89 Zr, 64 Cu) into an anti-EGFR antibody fragment allows same day imaging with positron emission tomography.
Publisher: Elsevier BV
Date: 05-2021
Publisher: American Chemical Society (ACS)
Date: 28-07-2020
Publisher: American Chemical Society (ACS)
Date: 07-04-2021
Publisher: Wiley
Date: 05-09-2019
Abstract: Molecules containing lysine-ureido-glutamate functional groups bind to the active site of prostate specific membrane antigen, which is overexpressed in prostate cancer. To prepare copper radiopharmaceuticals for the diagnosis and therapy of prostate cancer, macrobicyclic sarcophagine ligands tethered to either one or two lysine-ureido-glutamate functional groups through an appropriate linker have been prepared. Sarcophagine ligands can be readily radiolabeled with positron-emitting copper-64 at room temperature. The bivalent agent, in which two targeting groups are tethered to a single copper complex, dramatically outperforms the monomeric agent with respect to tumor uptake and retention. The high tumor uptake, low background, and prolonged tumor retention, even at 24 hours post injection, suggest the bivalent agent is a promising diagnostic for prostate cancer and could be used for prospective dosimetry for therapy with a copper-67 variant.
Publisher: American Chemical Society (ACS)
Date: 31-03-2021
DOI: 10.1021/ACS.BIOCONJCHEM.1C00109
Abstract: Radiolabeled derivatives of Tyr
Publisher: Elsevier BV
Date: 05-2021
Publisher: Society of Nuclear Medicine
Date: 15-05-2020
Publisher: Elsevier BV
Date: 05-2023
Publisher: American Chemical Society (ACS)
Date: 29-07-2020
Publisher: American Chemical Society (ACS)
Date: 26-07-2023
Publisher: Springer US
Date: 2023
No related grants have been discovered for Jessica Van Zuylekom.